Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma

S. A. Suttie*, A. E. Welch, K. G.M. Park

*Corresponding author for this work

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Aims: The aim of this review is to consolidate our knowledge on an important and rapidly expanding area of expertise. Numerous methods for predicting response (in terms of pathological response and survival) to neoadjuvant therapy (chemotherapy/chemo-radiotherapy) in oesophageal and junctional cancers have been proposed. This review concerns itself only with the use of positron emission tomography for such a purpose. At present there are no standardised criteria amongst PET trials as to what determines a response according to PET, what is the optimal time to perform PET in relation to the timing of neoadjuvant therapy, and what is the ideal method of quantifying PET tracer uptake. Methods: An electronic search was performed of PubMed, Ovid and Embase websites to identify studies, in the English language, using the search terms: PET; oesophageal; oesophago-gastric; survival; cancer; response; chemotherapy and chemo-radiotherapy. The reference lists were searched manually to identify further relevant studies. Results: Twenty-two studies were identified, all using 18FDG as the tracer, using PET to predict response in terms of pathological response and survival following neoadjuvant therapy (chemotherapy/chemo-radiotherapy). PET had a varying degree of success in predicting both pathological response and survival outcomes, with only one study using PET to influence management decisions. Conclusions: PET seems a promising technique, but large-scale conclusions are hindered by small study numbers, lack of criteria as to what constitutes a response and markedly differing PET imaging times. A large randomised trial concerning a homogeneous group of patients and tumours is required before PET might be used to influence management.

Original languageEnglish
Pages (from-to)1019-1029
Number of pages11
JournalEuropean Journal of Surgical Oncology
Volume35
Issue number10
DOIs
Publication statusPublished - 1 Oct 2009

Fingerprint

Neoadjuvant Therapy
Positron-Emission Tomography
Carcinoma
Radiotherapy
Survival
Drug Therapy
Fluorodeoxyglucose F18
Esophageal Neoplasms
PubMed
Neoplasms
Stomach
Language

Keywords

  • Chemotherapy
  • Oesophageal cancer
  • Positron emission tomography
  • Response

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma. / Suttie, S. A.; Welch, A. E.; Park, K. G.M.

In: European Journal of Surgical Oncology, Vol. 35, No. 10, 01.10.2009, p. 1019-1029.

Research output: Contribution to journalReview article

@article{c4e4482031d44c9fa62e19b0ba136e26,
title = "Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma",
abstract = "Aims: The aim of this review is to consolidate our knowledge on an important and rapidly expanding area of expertise. Numerous methods for predicting response (in terms of pathological response and survival) to neoadjuvant therapy (chemotherapy/chemo-radiotherapy) in oesophageal and junctional cancers have been proposed. This review concerns itself only with the use of positron emission tomography for such a purpose. At present there are no standardised criteria amongst PET trials as to what determines a response according to PET, what is the optimal time to perform PET in relation to the timing of neoadjuvant therapy, and what is the ideal method of quantifying PET tracer uptake. Methods: An electronic search was performed of PubMed, Ovid and Embase websites to identify studies, in the English language, using the search terms: PET; oesophageal; oesophago-gastric; survival; cancer; response; chemotherapy and chemo-radiotherapy. The reference lists were searched manually to identify further relevant studies. Results: Twenty-two studies were identified, all using 18FDG as the tracer, using PET to predict response in terms of pathological response and survival following neoadjuvant therapy (chemotherapy/chemo-radiotherapy). PET had a varying degree of success in predicting both pathological response and survival outcomes, with only one study using PET to influence management decisions. Conclusions: PET seems a promising technique, but large-scale conclusions are hindered by small study numbers, lack of criteria as to what constitutes a response and markedly differing PET imaging times. A large randomised trial concerning a homogeneous group of patients and tumours is required before PET might be used to influence management.",
keywords = "Chemotherapy, Oesophageal cancer, Positron emission tomography, Response",
author = "Suttie, {S. A.} and Welch, {A. E.} and Park, {K. G.M.}",
note = "The authors would like to thank Dr Marianne Nicolson (Consultant Oncologist. Department of Oncology, Aberdeen Royal Infirmary, UK) for her help.",
year = "2009",
month = "10",
day = "1",
doi = "10.1016/j.ejso.2009.01.012",
language = "English",
volume = "35",
pages = "1019--1029",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma

AU - Suttie, S. A.

AU - Welch, A. E.

AU - Park, K. G.M.

N1 - The authors would like to thank Dr Marianne Nicolson (Consultant Oncologist. Department of Oncology, Aberdeen Royal Infirmary, UK) for her help.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Aims: The aim of this review is to consolidate our knowledge on an important and rapidly expanding area of expertise. Numerous methods for predicting response (in terms of pathological response and survival) to neoadjuvant therapy (chemotherapy/chemo-radiotherapy) in oesophageal and junctional cancers have been proposed. This review concerns itself only with the use of positron emission tomography for such a purpose. At present there are no standardised criteria amongst PET trials as to what determines a response according to PET, what is the optimal time to perform PET in relation to the timing of neoadjuvant therapy, and what is the ideal method of quantifying PET tracer uptake. Methods: An electronic search was performed of PubMed, Ovid and Embase websites to identify studies, in the English language, using the search terms: PET; oesophageal; oesophago-gastric; survival; cancer; response; chemotherapy and chemo-radiotherapy. The reference lists were searched manually to identify further relevant studies. Results: Twenty-two studies were identified, all using 18FDG as the tracer, using PET to predict response in terms of pathological response and survival following neoadjuvant therapy (chemotherapy/chemo-radiotherapy). PET had a varying degree of success in predicting both pathological response and survival outcomes, with only one study using PET to influence management decisions. Conclusions: PET seems a promising technique, but large-scale conclusions are hindered by small study numbers, lack of criteria as to what constitutes a response and markedly differing PET imaging times. A large randomised trial concerning a homogeneous group of patients and tumours is required before PET might be used to influence management.

AB - Aims: The aim of this review is to consolidate our knowledge on an important and rapidly expanding area of expertise. Numerous methods for predicting response (in terms of pathological response and survival) to neoadjuvant therapy (chemotherapy/chemo-radiotherapy) in oesophageal and junctional cancers have been proposed. This review concerns itself only with the use of positron emission tomography for such a purpose. At present there are no standardised criteria amongst PET trials as to what determines a response according to PET, what is the optimal time to perform PET in relation to the timing of neoadjuvant therapy, and what is the ideal method of quantifying PET tracer uptake. Methods: An electronic search was performed of PubMed, Ovid and Embase websites to identify studies, in the English language, using the search terms: PET; oesophageal; oesophago-gastric; survival; cancer; response; chemotherapy and chemo-radiotherapy. The reference lists were searched manually to identify further relevant studies. Results: Twenty-two studies were identified, all using 18FDG as the tracer, using PET to predict response in terms of pathological response and survival following neoadjuvant therapy (chemotherapy/chemo-radiotherapy). PET had a varying degree of success in predicting both pathological response and survival outcomes, with only one study using PET to influence management decisions. Conclusions: PET seems a promising technique, but large-scale conclusions are hindered by small study numbers, lack of criteria as to what constitutes a response and markedly differing PET imaging times. A large randomised trial concerning a homogeneous group of patients and tumours is required before PET might be used to influence management.

KW - Chemotherapy

KW - Oesophageal cancer

KW - Positron emission tomography

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=69949171173&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2009.01.012

DO - 10.1016/j.ejso.2009.01.012

M3 - Review article

VL - 35

SP - 1019

EP - 1029

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 10

ER -